SCHEMBL2925601

SCHEMBL2925601

Cc1onc(-c2ccc(F)cc2F)c1CO

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 8/20 0.51
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.44
P2RX7 Q99572 3/20 0.43
ALDH1A1 P00352 1/20 0.43
GCGR P47871 1/20 0.43
DPP4 P27487 1/20 0.40
DHODH Q02127 1/20 0.39
KCNH2 Q12809 1/20 0.38
S1PR1 P21453 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926834 0.88 GABRA5 (0.51) GABRA5POLBMAPTTHRBP2RX7
SCHEMBL2929730 0.88 GABRA5 (0.51) GABRA5POLBMAPTTHRBP2RX7
SCHEMBL2931350 0.86 GABRA5 (0.53) GABRA5POLBMAPTP2RX7ALDH1A1
SCHEMBL2929241 0.82 GABRA5 (0.49) GABRA5MAPTALDH1A1GCGRDHODH
SCHEMBL19689508 0.81 NR1H4 (0.44) GABRA5
SCHEMBL30775156 0.81 NR1H4 (0.44) GABRA5
SCHEMBL286403 0.78 GABRA5 (0.52) GABRA5THRB
SCHEMBL3126454 0.77 POLB (0.45) GABRA5POLBMAPTTHRBP2RX7
SCHEMBL31559987 0.77 GABRA5 (0.39) GABRA5POLBMAPTTHRBGCGR
SCHEMBL2956539 0.77 ATM (0.54) GABRA5POLBMAPTTHRBP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0765725-B1 Process for injection molding polyethylene terephthalate A K TECH LAB INC (JP) 1999-12-15 EP claimed
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 US disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 EP disclosed
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-24 US disclosed
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-8518974-B2 Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (US) 2013-08-27 US disclosed
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-07-19 US disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
EP-1246865-B1 METHOD FOR PRODUCING A MODIFIED THERMOPLASTIC POLYESTER RESIN AND A FOAM ON THE BASIS THEREOF BUEHLER AG (CH) 2010-01-27 EP disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 US disclosed
EP-1246865-A1 METHOD FOR PRODUCING A MODIFIED THERMOPLASTIC POLYESTER RESIN AND A FOAM ON THE BASIS THEREOF Bühler AG (CH) 2002-10-09 EP disclosed
WO-2001051549-A1 METHOD FOR PRODUCING A MODIFIED THERMOPLASTIC POLYESTER RESIN AND A FOAM ON THE BASIS THEREOF Bühler AG (CH) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 GABRA5 1/4885POLB 3831/4885MAPT 254/4885
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 GABRA5 1/4885POLB 3764/4885MAPT 255/4885
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 GABRA5 1/4885POLB 3764/4885MAPT 255/4885
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 GABRA5 1/4885POLB 3764/4885MAPT 255/4885
US-20130274469-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 GABRA5 1/4885POLB 3764/4885MAPT 255/4885
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 GABRA5 1/4885POLB 3764/4885MAPT 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.